ArcherDXpharma
Jun 23, 2020
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result
Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases The engineered exosome technology is believed to improve the delivery of delivering gene therapy, gene editing and RNA technologies for ne...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
